Atea Pharmaceuticals AVIR
NASDAQ AVIR
$5.13 +0.03 (+0.59%)
At close: Oct 2, 2026 · 4:00 PM EDT

Atea Pharmaceuticals (AVIR) Price to Sales (2021)

Updated

Atea Pharmaceuticals' Price to Sales was 2.11 in Q4 2021.

Analysis

Atea Pharmaceuticals (AVIR) Price to Sales (2021) Analysis & Trends

  • In earlier years, Price to Sales was 18.55 in FY2020.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Atea Pharmaceuticals 411.45 Mn 411.45 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2021 2.11
API Access

Atea Pharmaceuticals Price to Sales API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=price-to-sales&ticker=AVIR&period=max&api_key=YOUR_API_KEY